There’s a new biotechnology company on the Nasdaq. And they’re aiming to change the future of natural tissue repair.
What’s happening:
Regenerative tissue platform company Conexeu Sciences (NASDAQ: CNXU) has successfully completed a direct listing and begun trading on the Nasdaq
Why it matters:
Conexeu Sciences has developed a regenerative tissue platform that is the foundation of their lead device candidate known as Ten Minute Tissue that starts as a injectable liquid and then turns into a stable gel at body temperature for wound care and rapid treatment of burns
Going deeper:
More than a decade of preclinical university research was done to develop Conexeu Sciences’ bioregenerative extracellular matrix platform and Conexeu Sciences has been issued patents in the United States, Japan, Australia and the European Union that protects their proprietary regenerative tissue platform
Conexeu Sciences has publicly stated that they are aiming to leverage their regenerative tissue platform for wound care, aesthetics, GLP-1 driven skin laxity, 3D bioprinting and biofabrication
The intrigue:
Conexeu Sciences is pursuing a predicate based regulatory strategy with the United States Food and Drug Administration with a 510(k) submission to obtain clearance to use their Ten Minute Tissue product as a collagen based scaffold for wound care
